SCHEMBL9753613

SCHEMBL9753613

CCOC(=O)c1cn2c(CC=CP(=O)(OCC)OCC)cccc2n1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.58
MAPK1 P28482 1/20 0.41
CYP1A2 P05177 2/20 0.41
KDM4E B2RXH2 7/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
GABRA2 P47869 3/20 0.38
GABRB2 P47870 3/20 0.38
RXFP1 Q9HBX9 1/20 0.37
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9753611 1.00 GAA (0.58) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL8889397 0.83 GAA (0.60) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL8889403 0.83 GAA (0.60) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL8609864 0.82 GAA (0.68) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL8607711 0.81 GAA (0.64) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL9753595 0.80 GAA (0.61) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL8610256 0.80 GAA (0.71) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL7274660 0.79 GAA (0.75) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL8607723 0.79 GAA (0.67) GAAMAPK1CYP1A2KDM4EPOLB
SCHEMBL118407 0.78 GAA (0.73) GAAMAPK1CYP1A2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0436831-A2 Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury G.D. Searle & Co. (US) 1991-07-17 EP disclosed
WO-1991008211-A1 IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY G.D. SEARLE & CO. (US) 1991-06-13 WO disclosed